Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU2-51P (RNA, U2 small nuclear 51, pseudogene) is classified as a pseudogene, corresponding to a region in the human genome that resembles the functional U2 small nuclear RNA genes but does not encode a functional product[4]. Pseudogenes like RNU2-51P typically arise via duplication or retrotransposition events and lack protein-coding potential or regular biological activity. Unlike functional U2 snRNAs (such as those encoded by RNU2-1 or RNU2-2), there is no evidence that RNU2-51P is involved in splicing or other cellular processes. It is annotated and cataloged in genome databases but is not regarded as a gene or therapeutic target[4]. There is no known association of RNU2-51P with disease or therapeutic interventions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U2 small nuclear 51, pseudogene (RNU2-51P).